The Paclitaxel Drug-Coated Device Controversy: Case Closed?

article image
ARTICLE SUMMARY:

New data presented at this year’s virtual TCT conference could help put to rest safety fears around the use of paclitaxel coated devices in the peripheral vasculature. That’s good news for medtech companies eager for a market recovery.

Study data presented at this year’s virtual Transcatheter Cardiovascular Therapeutics (TCT) meeting, held in mid-October, strongly suggest that safety fears over the use of paclitaxel drug-coated balloons and stents in the periphery should be put to rest, according to several physicians who spoke during the conference.

×



This article is restricted to subscribers only.

Sign in to continue reading.

Questions?

We're here to help! Please contact us at: